



## JOINT TRANSNATIONAL CALL 2015:

## "Immunology and Immunotherapy of Cancer: Strengthening the Translational Aspects"

## PARTNER REQUEST/COLLABORATION OFFER

If you would like to have your profile published on our "Search for a research partner" webpage, please fill out this form and send it to 

If you have any questions about this form, please do not hesitate to contact us at 

**Note:** Fields marked with a \* are mandatory

General Information	
First name *	Gilles
Last name *	MARODON
Position *	Research associate
Telephone number	+33 645 152948
E-mail address*	Gilles.marodon@upmc.fr
Website address:	<a href="http://www.cimi-paris.upmc.fr/index.php/fr/">http://www.cimi-paris.upmc.fr/index.php/fr/</a>
Institution/Organisation *	Sorbonne Universités- CIMI-PARIS
Department	INSERM U1135 CNRS ERL 8255
Street *	91 Bd de l'Hopital
Postal Code * / City *	75013 PARIS
Country *	FRANCE

\* I agree with the publication of my contact data and of this form on the TRANSCAN Website:

YES

## SEARCH FOR A COLLABORATOR

IF YOU ARE LOOKING FOR A PARTNER IN YOUR SUGGESTED PROPOSAL, PLEASE SPECIFICY ALSO THE NEEDED EXPERTISE

Project proposal	
Project title	
Provide a short project description about the project and the consortium (Max. 450 words)	

## OFFER FOR COLLABORATION

IF YOU PROPOSE YOURSELF AS A PARTNER IN A CONSORTIUM, PLEASE DETAIL YOUR EXPERTISE

OFFER FOR COLLABORATION	
Type of partner (Research institution, university, etc.)	Any type
Provide a short description about the expertise (Max. 200 words)	
<p>Our group was funded by institutional and private funds to validate the use of therapeutic antibodies for cancer immunotherapy in humanized mice. Compared to mouse models, the humanized mice model may allow for a more rapid translation of the results to humans. Our results so far show that humanized mice is a promising model to assess immune rejection based on allogenic rejection. We would like to show that the model might be also suited to detect immune responses to mutated antigens expressed by human tumors. Moreover, this model might be used as a personalized medicine model to asses the efficacy of vaccines in combination with immunotherapy using monoclonal antibodies. This might be achieved by grafting tumors and PBMCs from the same patient and applying various treatments to induce immune rejection. Our group is currently composed of one postdoc and 2 PhD students dedicated to the models. Our group is located in a public research center equipped with the most recent technologies for assessing complex immune responses, such as Cytometry time-of-Flight (Cytof) or 18-colors flow cytometry. The efficacy of our projects will greatly improve if we would have the possibility to hire extra hands to perform experiments and extra brains from the consortium.</p>	